HYMOVIS ONE® is a sterile, hydrogel manufactured with HYADD®4: (hexadecylamide of highly purified natural sodium hyaluronate obtained by bacterial fermentation)4
Thanks to the high viscosity and elasticity given by the hexadecylamide of sodium hyaluronate, HYMOVIS ONE® improves the lubricating and shock absorbing function of synovial fluid, protecting cartilage and soft tissues against mechanical injuries4
These properties, together with the prolonged residence time in the articular joints, enable HYMOVIS ONE® to relieve pain and to improve joint function, in mild or moderate hip and knee osteoarthritis of any origin, up to six-twelve months2
why monoinjection?
Reduces visits1 and enhances compliance2
Rapid and minimally invasive procedure2
Rapid and long lasting response2
HYADD®4
HYADD®4 is an innovative hyaluronic acid hydrogel developed by Fidia Farmaceutici, marketed under the brand name HYMOVIS®. This advanced formulation features a unique hexadecylamide derivative of hyaluronic acid, enhancing its viscoelastic properties and prolonging its residence time in the joint
HYADD®4 is designed to provide effective viscosupplementation, improving joint lubrication and cushioning, which can significantly alleviate pain and improve mobility in still very active patients with osteoarthritis.
Clinical studies have demonstrated its efficacy in reducing symptoms and enhancing the quality of life for high demand patients with OA.
The hydrogel is administered via intra-articular injection, offering a promising alternative for those who have not responded well to conventional treatment.
WHAT IS HYMOVIS ONE®?
HYDROGEL
4th generation intra-articular HA based product MD3
HYADD®4
Hexadecylamide of highly purified natural sodium hyaluronate obtained by bacterial fermentation4
MO.RE. (MObile REticulum) TECHNOLOGY
Composition
HYADD®4:
(hexadecylamide of highly purified natural sodium hyaluronate obtained by bacterial fermentation)4 32 mg/4mL
Available Presentation
Box containing 1 pre-filled syringe4
Indications
HYMOVIS ONE® is indicated for the treatment of patients affected by mild or moderate osteoarthritis of the knee and hip. The device is indicated for the treatment of OA of any origin4
Dosage & Administration
HYMOVIS ONE® is intended in monoinjection regimen for intra-articular injection only4
Product portfolio
VISCOSUPPLEMENTATION
Medical Devices CE0459.
Read the instructions for use carefully.